Clinical Trial Update: Beta 3 Agonist Treatment in Heart Failure-2 [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial update for a beta-3 agonist in heart failure with reduced ejection fraction (NYHA class III–IV) has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Snippet

Sponsor: Henning Bundgaard | Conditions: Heart Failure With Reduced Ejection Fraction NYHA Class III-IV | Phase 2, Phase 3 | Status: COMPLETED